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Abstract 
 The prevalence of chronic liver disease is increasing in the elderly population.  
With a mostly asymptomatic or non-specific presentation these diseases may 
easily go undiagnosed.  Abnormal liver function tests of unknown cause are a 
common reason for referral to secondary care.  Investigating the older person 
with abnormal liver function is important; even with mild abnormalities the 
same vigilance should be applied to an older person as in a young person.  
Liver biopsy is safe but often overlooked in this age group, and may provide 
useful information to diagnose, direct therapy and prognosticate.  Treatment 
options are similar for all age groups, with a few subtle differences, although 
further evidence is frequently required for the older population.  Morbidity and 
age adjusted mortality are often more severe in older people, and therefore 
early diagnosis and intervention is important.  Presented here are the most 
common chronic liver diseases that geriatricians are likely to encounter in 
clinical practise.  Their epidemiology, clinical features, investigation, treatment 
and mortality are described with a particular focus on the elderly population. 
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Introduction 
No liver disease is specific to old age; however as the population ages 
geriatricians are frequently managing older patients with chronic liver 
diseases.  Presented here are some of the more common, chronic diseases 
to affect the liver and how their clinical features, investigations, treatment and 
mortality are affected by advancing age.  The epidemiological characteristics 
of each disease are presented in table 1. 
 
Please see Appendix 1 in the supplementary data on the journal website 
(http://www.ageing.oxfordjournals.org/) for search strategy and selection 
criteria. 
 
Basic Science 
 
The liver has a remarkable ability to regenerate and maintain function during 
the ageing process.  There are, however changes on a cellular and 
physiological level which reduce the overall function of the liver. 
 
Despite compensatory cell hypertrophy, in response to the decreased number 
of hepatocytes seen with ageing, in liver size reduces by 25% between the 
age of 20 and 70; with a 33% reduction of hepatic blood flow in over 65 year 
olds [1]. 
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The aged liver takes on a dark, macroscopic appearance, resulting from the 
accumulation of intracellular debris that may arise from defective protein 
synthesis and degradation [1]. 
 
Activity in hepatic cytochrome P450 oxidation is reduced with age, as is the 
protective enzyme superoxide dismutase, both of which may contribute to 
increased sensitivity of hepatocytes to xenobiotics [2].  Reduction in protective 
enzymes, a decline in response to growth factors and a theoretical risk of 
increased pathogen load from the gut all put the aged liver at increased risk of 
disease [3]. 
 
Investigations 
 
Laboratory markers of liver disease [liver function tests (LFTs): bilirubin, 
transaminases, hepatic alkaline phosphatase (AP)] do not change with 
advancing age.  Hepatic alcohol dehydrogenase also has no age related 
reduction in function; it is worth noting however that gastric alcohol 
dehydrogenase is found in lower levels in the elderly [4, 5]. 
 
Liver biopsy is a safe in the elderly, with 6% of liver biopsies in England and 
Wales being performed in over 80 year olds.  The mortality in this age group 
having liver biopsy is 0.13-0.33%, with no increase in mortality seen with 
advancing age [6]. 
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General Management Principles in Advanced Liver Disease 
 
Ascites is a feature of advanced liver disease related to cirrhosis.  In addition 
to sodium and water restriction, which patients often find unpalatable and 
tolerate poorly, the 2003 Consensus recommends the use of anti-
mineralocorticoids [7].  There are no age related absolute contraindications to 
diuretics, however some adverse effects may be more severe with advancing 
age.  Elderly patients with cirrhosis are more likely to suffer from disturbed 
fluid balance homeostasis; leading to orthostatic hypotension as a result of 
low intra-vascular volume, exacerbated by diuretic use.  Furthermore, older 
patients prescribed diuretics are at increased risk of incontinence. 
 
Paracentesis is recommended for ascites unresponsive to medical therapy.  
There are no age related contraindications, however most trials have not 
included patients beyond the age of 65 years [8, 9]. 
 
Transjugular intrahepatic portosystemic shunt (TIPS) is effective for refractory 
ascites and for uncontrolled variceal bleeding.  It should be considered if 
paracentesis is required more than 3 times per month [7].  TIPS is more 
effective at improving sodium excretion in those who are aged less than 60 
years.  Whether or not complications are more common in the elderly is 
controversial; some studies noted an increased incidence of post-TIPS 
hepatic encephalopathy in subjects over 60 years, but this has not been 
confirmed in further studies [10, 11, 12]. 
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The use of lactulose is recommended in minimal hepatic encephalopathy as it 
improves cognition and quality of life.  It has not however, been shown to 
prevent progression of hepatic encephalopathy or improve survival [13].  Care 
should be taken when treating the elderly with laxatives;  malabsorption, 
dehydration, electrolyte imbalance and faecal incontinence are all more likely 
to occur [14]. 
 
Liver Transplantation 
The mean age of liver transplantation in 1985 was 29 years, increasing to 41 
years by 1995 [15].  The proportion of over 60 year olds who received liver 
transplants in 1990-1991 was 10%, doubling to 21% in 1997-1999 [16]. 
In a study following 478 liver transplant recipients over 13 years, comparing 
over and under 60 year olds, there were no significant differences in length of 
hospital stay, repeat admissions, infections, rejection or repeat transplantation 
[17]. 
Five and 10 year survival in over 60 year old recipients was significantly 
reduced (52%, 35%)  when compared to an under 60 year old group (75%, 
35%) in one study.  Conversely, other studies demonstrate that there are no 
significant survival differences between older and younger patients if they are 
classified as low risk pre-treatment. Factors which contribute to significantly 
worse mortality in the elderly include being in hospital pre-transplant, low 
albumin, raised bilirubin, raised prothrombin time and a high Child-Pugh score 
[16, 17, 18]. 
The commonest cause of death in recipients over 60 is malignancy (35%).  
This is significantly greater than in younger patients who are most likely to die 
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from infection [17].  Cerebro- and cardio-vascular death rates are similar in 
both age groups, as the elderly group undergo more pre-transplant screening 
for comorbidities. 
 
Alcoholic Liver Disease (ALD) 
Clinical Features 
The very old are more likely to have signs of severe liver disease on 
presentation, than the young.  The commonest presentations in the older 
patient are non-specific and include general malaise, anorexia and abdominal 
pain.  In those aged over 70, dizziness is one of the most common 
presentations.  Jaundice, oedema and ascites are more common in the older 
than in the young, suggesting a more severe stage of ALD at presentation 
[19, 20]. 
 
Investigations 
Older patients have histologically more advanced liver disease compared to 
younger patients; however this may not be apparent on routine laboratory 
tests which show no significant differences between older and younger 
patients.  The most common abnormalities found in those over 60 are 
elevated serum aspartate aminotransferase (AST) and bilirubin, increased 
mean corpuscular volume and raised AP [19, 20].  Importantly, one study 
which biopsied 96% of it’s subjects, identified that 100% (n = 7) of men aged 
over 70 year presenting with ALD had cirrhosis on biopsy, compared to 55% 
(n=112) in men aged 20-59 years [20]. 
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Treatment 
There are no specific differences in the treatment of the older patient.  
However, blood alcohol levels may be higher in the elderly per unit consumed 
because of the lower body water content in which it is distributed.  Acute 
withdrawal can easily be missed in the elderly patient, and may require 
treatment with sedatives.  Benzodiazepines are commonly used to treat or 
prevent withdrawal symptoms but their distribution can be affected in the 
elderly who have a higher proportion of fat; the resulting prolonged half-life 
could result in prolonged sedation.  Adverse effects associated with 
benzodiazepines are more common in the elderly; drowsiness, fatigue, 
confusion, ataxia, falls and incontinence are significantly more common with 
increasing age [21]. 
 
Mortality 
One year mortality following diagnosis of cirrhotic ALD is 34% in the over 60s, 
significantly greater than those below 60 (5%).  Of those over 60 who die, 
87% have liver related deaths; the commonest causes being hepatorenal 
failure, gastrointestinal bleeding and cardiomyopathy.  The commonest cause 
of death in men under 60 is myocardial infarction [19, 20]. 
 
Non Alcoholic Fatty Liver Disease (NAFLD) 
Clinical Features 
The natural history and pathogenesis of NAFLD is increasingly being 
understood, with insulin resistance being a central factor.  Known risk factors 
are obesity, hypertriglyceridaemia, hypertension and type 2 diabetes.  Raised 
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serum fasting insulin and c-peptide indicate insulin resistance and may 
contribute to the diagnosis in non-diabetics. 
 
Treatment 
In order to prevent progression from steatosis to fibrosis risk factors should be 
addressed as early as possible.  A reduction in total daily energy intake with a 
10% weight reduction does improve metabolic and histological abnormalities; 
this benefit is augmented with exercise (burning 400 calories, 3-4 times per 
week) [22].  However, it is not yet clear whether the elderly will benefit to the 
same extent as the young from this intervention. 
 
Mortality 
Age is an independent risk factor for  severe fibrosis in NAFLD (odds ratio  5.6 
in those aged >45 years) [23, 24], whether this is due to impaired 
regeneration and recovery of the liver to inflammatory insults, or whether it is 
because the older have had NAFLD for longer, is not known.  Increased risk 
of death is also significantly linked to advancing age (p<0.0001) [25].  In a 
population based study of 435 patients with NAFLD (mean age 49 ± 15 years) 
survival over 10 years follow up was significantly less than the general 
population (standardised mortality ratio 1.34, p=0.03) [25]. 
 
Autoimmune Hepatitis (AIH) 
 
Clinical Features 
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There are no differences in clinical presentation between younger and older 
patients with AIH, with both more likely to have an insidious rather than an 
acute onset.  Retrospective review of 54 patients over 65 years found 20% 
were asymptomatic on presentation, approximately 50% had non-specific 
symptoms (lethargy, pruritus, abdominal pain) and around 25% were 
jaundiced or showed signs of hepatic failure [26].  A larger systematic, 
retrospective analysis of AIH patients found that patients aged over 65 years 
were significantly more likely to have ascites on presentation than younger 
patients (30% vs 9% p<0.001), suggesting a more severe stage of the 
disease [27, 28]. 
 
Autoimmune disease associations are similar in the old compared to the 
young, but younger subjects have a more diverse ‘catalogue’ of disease 
associations (Table 2) [28, 29, 30]. 
 
Investigations 
No significant differences exist with advancing age in laboratory tests, 
including AP, serum transaminases, gammaglutamyl transpeptidase, bilirubin, 
serum immunoglobulins (raised IgG), anti-nuclear antibodies, smooth muscle 
antibodies, and type 1 liver-kidney microsomal antibodies [28, 29, 31].  It is 
unknown whether older patients with AIH are less likely to have a liver biopsy 
as clinical trials and reviews focus on patients with confirmed histological 
diagnosis. 
 
Treatment 
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Treatment strategies are identical for all adult ages.  Prednisolone alone or 
prednisolone with azathioprine prescribed as initial therapy has been used at 
equal rates with equal outcomes in the elderly and the young [29, 31].  The 
same is true for maintenance therapy with prednisolone alone, prednisolone 
with azathioprine or azathioprine alone [29].   
 
Responses to immunosuppression are generally excellent in AIH irrespective 
of the presence of cirrhosis [32, 33].  The significance of relapses between the 
two groups is not clear, with contradicting results [28, 29].  No difference has 
been seen in rates of liver transplant between older and younger patients, nor 
in their mortality [28]. 
 
Measurements of baseline bone density are of use in all age groups, and 
treatment/prevention directed as appropriate. 
 
Mortality 
Most patients with AIH die of non-liver related disease.  One study has noted 
that in over 65 year olds no deaths were related to liver disease, but in the 
under 65 years group 7% died as a result of complications of chronic liver 
disease [26]. 
 
Primary Biliary Cirrhosis (PBC)  
 
Clinical Features 
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The majority of patients are asymptomatic on presentation, however younger 
patients are significantly more likely to have non-specific symptoms compared 
to those over 65 years (Sjogren’s syndrome, pruritus, weight loss, 
xanthelasma, fatigue, abdominal discomfort) [34]. 
 
Investigations 
No differences in laboratory data occur between older and younger PBC 
patients.  AP is likely to be the most deranged liver function test, followed by 
alanine aminotransferase (ALT), bilirubin and albumin.  Anti-mitochondrial 
antibody is present in 95% of patients [35], a raised IgM may also be present.  
Older patients are significantly less likely to have a liver biopsy for histological 
confirmation/diagnosis, but have significantly more advanced histological 
staging when they do undergo biopsy [34]. 
 
Treatment 
Ursodeoxycholic acid may have some benefit in PBC patients, however 
further studies are required to explore long term outcome.  Transplantation is 
the only curative option, but rarely undertaken in the very old. 
 
Mortality 
Liver related deaths are significantly more frequent in the over 65 year olds 
when compared to under 65 year olds, but overall non-liver related deaths are 
more common [34].  Patients aged over 65 years with fatigue have 
significantly greater mortality than those over 65 without fatigue; the fatigued 
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over 65 year olds also have higher mortality compared to those aged less 
than 65 with fatigue (9.3% vs 1.4% per year of follow-up) [36]. 
 
Primary Sclerosing Cholangitis (PSC) 
Increasing age is an independent risk factor for a poor outcome [37].  
However, very little data exists on PSC in the elderly, perhaps because the 
median age of diagnosis is 40 years with a median survival of 11.9 years, and 
because it is itself a rare disease.  However, with a second peak in the 
incidence of inflammatory bowel disease in the 7th-8th decade [38], and 
survival of IBD patients similar to that of the general population, we may 
expect to see more PSC in the elderly [39]. 
 
Viral Hepatitis- Hepatitis B 
 
Clinical Features 
Clinical features of HBV infection in the elderly were noted during one 
outbreak in a nursing facility.  Symptoms (anorexia, vomiting and jaundice), as 
expected, were present in only a few cases, and are typical of HBV in any age 
[40].   
 
Investigations 
In the aforementioned outbreak, ALT was transiently raised in those with 
transient HBV, in those with persistent infection ALT was fluctuant initially and 
returned to normal in all patients.  Nine of the 31 patients who were initially 
positive for HBsAg were negative at 6 months, and therefore infected only 
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transiently.  In 13 of the 22 cases followed up at 6 months HBsAg persisted, 
with a resultant carrier rate of 59%.  Although these numbers are very small 
no association was seen between age and carrier rate [40].  Residents of 
nursing homes may be at increased risk of contracting HBV, and with 
relatively high transmission rates this group of people should be considered 
for vaccination [41]. 
 
Clinically HBsAg, anti-HBsAg, HBeAg, anti-HBeAg and HBV-DNA are the 
most useful investigations guiding treatment and prognosis, by providing 
details of active viral replication and staging.  However, HBV DNA and HBeAg 
are generally low or absent in the elderly, resulting in fewer elderly patients 
being treated [42]. 
 
Treatment 
Treatments include interferon or pegylated interferon, and the antivirals 
lamivudine, adefovir, entecavir and telbivudine, or a combination of these.  In 
general, interferon (given as 3 subcutaneous injections per week) and 
pegylated interferon (one subcutaneous injection per week) are given for a 
fixed period, usually 6-12 months, and offer sustained ‘off-therapy’ responses.  
Antiviral agents have fewer side-effects and better tolerability and can be 
given for longer periods.  Lamivudine is the most widely used agent but 
emergence of resistant strains is higher than with the other antivirals.  
Adefovir has better longer term outcomes and is also indicated in lamivudine 
resistant HBV.  Resistance to entecavir is rare and it is more potent than the 
other antivirals at reducing HBV DNA at end of therapy.  The use of 
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telbivudine is unclear at present because of its unfavourable resistance profile 
[43]. 
 
The efficacy of some treatments has not been assessed specifically in the 
elderly, however some trials do include elderly subjects, including a meta-
analysis of randomised controlled trials assessing the efficacy of combination 
interferon with lamivudine versus interferon alone – equally effective in 
younger and older groups [44].  Assessment of lamivudine in the elderly has 
shown that it is as effective in both over and under 60 year olds at reducing 
ALT and HBV DNA, with resistance no more prevalent in the older group [45].   
 
Mortality 
Older patients have a much greater chance of developing hepatocellular 
carcinoma (HCC) – 927/100 000 in 60-69 year olds, compared to 197/100 000 
in 30-39 year olds [46]. 
   
Viral Hepatitis- Hepatitis C 
 
Clinical Features and Investigations 
In a study of 25 patients aged over 65 the presenting features in order of 
occurrence were abnormal liver function tests (LFTs), bleeding oesophageal 
varices, malaise, abdominal pain, oedema and pruritus.  Each patient had 
abnormal LFTs.  Twenty underwent liver biopsy at presentation, 60% had 
cirrhosis, 30% had cirrhosis and HCC and 10% had chronic hepatitis [47]. 
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Treatment 
Recombinant interferon has a response rate (normalised ALT, improved liver 
histology) of 62% in the over 65s, compared to 57% in under 65 year olds.  
Side effects however, are more common in the older patients (23%) 
compared to the young (19%) [48].  Combination interferon and ribavirin is as 
successful in the over 60s as the under 60s, with a sustained virological 
response of 38% in the under 60s and 32% in the over 60s (p=0.36).  
Combination is also more effective than interferon alone, and is not 
associated with more side effects than the under 60s [49]. 
 
Mortality 
In a 10 year follow up of an elderly population, 34% died and of those only 
17% were related to liver disease (liver failure, HCC) [50]. 
 
Hepatocellular Carcinoma 
 
Clinical Features 
Signs and symptoms at presentation are similar for older and younger 
patients.  Typical presentation is of an acute deterioration in an existing 
chronic liver disease, necessitating the need for screening [LFTs, alpha-
fetoproetein (αfp), liver ultrasound].  In patients over 65 years the commonest 
presenting symptoms are weakness, abdominal pain, anorexia, weight loss 
and nausea.  Presenting clinical signs in one retrospective study of the over 
65s were hepatomegaly (in 85%), jaundice and ascites (in 35% of patients) 
[51]. 
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Investigations 
AP, AST and albumin are abnormal in over 80% of over 65 year olds, and 
bilirubin and ALT abnormal in over 60%.  Alpha fetoprotein is >10 ng/ml in 
90% of over 65 year olds, and >200 in 63%.  HBsAg can be found in 13% of 
over 70 year olds with HCC, which is significantly less than those aged under 
70 years [52].  Sixty-nine per cent of over 65 year olds have cirrhosis, a 
similar figure to a younger group [51].  The stage of HCC (Okuda: bilirubin, 
albumin, ascites, tumour size) was not different between age groups [51]. 
 
Treatment 
No significant differences in complications, survival months, intensive care 
admissions and mortality is seen between age groups receiving liver resection 
[53].  Potentially curative therapies exist for patients with HCC; including 
resection, transplantation and local ablation.  In addition to these treatment 
methods, trans-arterial chemo embolisation (TACE) can palliate and prolong 
survival.  One large, population-based study of older patients with HCC, 
(compared to younger patients in brackets), were treated as follows: 
transplant 0.9% (1.5%), tumour resection 8.4% (5.9%), ablation 4.1% (4.4%), 
TACE 4.2% (6.3%) [54]. 
 
Mortality 
In the above study, 3 year survival was best in transplanted patients (40.7%), 
followed by resection (30.9%), ablation (9.8%) and TACE (6.1%) [54]. 
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Other Chronic Liver Diseases 
 
Haemochromatosis 
Hereditary Haemochromatosis (HH) is classically diagnosed in middle age, 
with an average survival of 21 years (with treatment) [55]. However, recent 
case reports and genetic studies confirm that it can present in old age, and 
males who are homozygous for the C282Y gene (the commonest genetic 
abnormally identified) are surviving into old age without clinical or biochemical 
abnormalities.  This is of importance to the geriatrician who should recognise 
that patients can present much later than previously thought [56].  As might be 
expected, females who undergo earlier menopause have a greater 
concentration of hepatic iron, than females who undergo the menopause after 
the age of 50, as a result of therapeutic menstruation [57].   
HH must also be considered in older patients presenting with neurological 
complications, as iron overload may be misdiagnosed with movement 
disorders such as Parkinson’s disease or cerebellar syndromes [58].   
Treatment of HH by venesection may induce orthostatic hypotension as a 
result of volume loss which is likely to be more severe in the elderly; 
concomitant infusion of intravenous fluids may reduce this risk. 
 
α-1 Antitrypsin Deficiency (A1ATD) 
A1ATD is recognised as a possible cause of cirrhosis in older age.  In one 
case review describing 3 patients, aged over 65, only one had obstructive 
airways disease, but each had abdominal swelling or hepatomegaly; with a 
raised ALP.  A1AT is an inflammatory marker making interpretation of levels 
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less useful for diagnosis which is confirmed on liver biopsy [59].  A1ATD can 
also present with respiratory disease in the elderly, and is more likely to 
present later in age in life-long non-smokers [60]. 
 
Wilson’s Disease (WD) 
The commonest presentation in adulthood is neuro-psychiatric, compared to 
hepatic dysfunction in childhood [61].  Case reports of WD presenting in the 
elderly however are less typical.  Reports vary from neurological dysfunction 
in the absence of liver disease and Kaser-Fleischer rings [62], liver disease 
with no neurological dysfunction [63], to non-specific presentation (weight 
loss) [64].  In one review comparing recent diagnoses of WD (1994-2003) to 
past diagnoses (1976-1993) the age at presentation was greater in the most 
recent period (35.1 vs 16.7 years) [65]. 
 
Conclusions 
It is important that Geriatricians recognise that the prevalence of liver disease 
is increasing in older age groups, including rarer liver diseases.  Awareness of 
vague symptoms and signs which could indicate liver abnormalities and 
interpretation of investigations such as LFTs is vital.  The same vigilance 
should be applied to older patients as it is to younger patients when 
interpreting abnormal LFTs, no matter how mild the abnormality.  In diagnostic 
uncertainty liver biopsy is safe, but often overlooked, and may lead to 
appropriate treatment.  Special attention should be paid to those who are 
prescribed diuretics, lactulose and benzodiazepines as adverse effects are 
more common in the elderly.  The science behind the ageing liver would 
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suggest that it is less able to cope with insults and may contribute to more 
severe disease or decompensate existing disease. 
 
 
 
 
 
Table 1   
Summary of the epidemiology specific to older age groups with chronic liver disease 
 Epidemiology 
 
ALD 53% of men and 38% of women aged over 60 years are current drinkers [66].  28% of ALD diagnoses are in patients aged 60 or over.  8% of patients 
aged over 65 years who were admitted acutely to hospital are abusers of alcohol; and of those, 24% are admitted because of alcohol related problems 
[67]. 
 
NAFLD As the incidence of obesity and type 2 diabetes increases the prevalence of NAFLD will also increase, particularly in the elderly  [68, 69]. In type 2 
diabetics the prevalence of NAFLD is 65.9%, with those aged 40–59 the prevalence is 65% whilst in those aged over 60 years it is 75% (p <0.001) [68].  
In the general population NAFLD may affect 10 – 24% and >90% of those who are morbidly obese. 
 
AIH In patients aged over 65 years there is a 1:9 male to female ratio.  It can present in any age group  but several recent studies suggest a bimodal age 
distribution peaking at puberty and the menopause, with some reporting a greater peak in the older group [27, 28, 29]. 
 
PSC Although the mean age at diagnosis of PSC is 40 years, with time patients are becoming older at diagnosis [70, 71].   
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PBC The prevalence of PBC may be as high as 35 per 100000, with higher incidence in middle age.  In females aged over 45 years in the North of England 
the incidence is 1 in 700 [35].  Median age of onset is 50 years [72] with  50% at presentation being over 65 years. 
 
Hep B The prevalence of the HBsAg in a western, European hospital remained stable over the period 1993 – 2003, at 0.7%.  The prevalence in relation to 
advancing age decreased to nil from age 35 to age 65 and above.  In this population 0.9% of over 65 year olds had been vaccinated against HBV 
compared to ~21% in the 35-44 year old group [73].  42% of older subjects (mean age 74) respond to vaccination, compared to100% of controls (mean 
age 28) [74, 75].  Outbreaks have been described in nursing homes, risk factors include sharing bath brushes, sexual contact, non-disposable syringes 
and shaving blades [76, 77, 78].   
 
Hep C The prevalence of HCV in asymptomatic blood donors in the United Kingdom is 0.2% [79].  In the elderly population anti-HCV may be present in up to 
4.5% of nursing home residents, with previous blood transfusion being associated with the presence of the antibody [80].  The mean age of patients with 
HCV is 40 years, mean age of HCV with cirrhosis is 65 years, and the mean age of HCV with HCC is 70 [81], suggesting that HCV complications are 
more prevalent in the elderly. 
 
HCC The incidence in North America and Northern Europe is <5.0/100 000 [82].  15-31% of patients with HCC are aged over 70 years [51, 52, 83].  It is a 
complication of liver disease of any cause, but may also be related to toxins such as alfatoxin (contaminated foodstuffs) and vinyl chloride (factory 
workers) [84]. 
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Figure 1 
Investigation and management of older people with liver disease (Ig’s = immunoglobulins, AMA = anti-mitochondrial 
antibody, ERCP = endoscopic retrograde cholangiopancreatography, USS = ultrasound scan, URDA = ursodeoxycholic 
acid, s/c = subcutaneous, OH = orthostatic hypotension, ↑ = increased) 
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USS 
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USS 
Mass ± 
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liver disease 
USS 
Fibrosis 
USS 
Fibrosis 
USS USS 
Fibrosis 
USS 
To assess for steatosis, cirrhosis or masses ± signs of portal hypertension 
Liver biopsy (if indicated) 
To confirm diagnosis, direct therapy and prognosticate 
Management 
Focussing on older patients 
Falls risk, 
Capacity, 
Nutrition, 
Caution with 
benzodiazepines 
Address risk 
factors, 
Encourage 
exercise - 
address joint 
pains 
Immuno-
suppression, 
osteoporosis risk, 
poly-pharmacy 
URDA,  
osteoporosis risk 
URDA, 
steroids, 
azathioprine, 
endoscopy/ 
surgury 
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interferon, 
polypharmacy 
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interferon, 
polypharmacy 
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required for 
inhalers 
(pulmonary 
involvement) 
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reduced iron 
absorption, 
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Liver Transplantation (if indicated) 
 Table 2   
Disease associations seen in Autoimmune Hepatitis 
Conditions seen in younger AIH 
subjects 
Conditions seen in the over 65 year 
olds 
Rheumatoid Arthritis Rheumatoid Arthritis  
Autoimmune Thyroid Disease Autoimmune Thyroid Disease 
Ulcerative Colitis Ulcerative Colitis 
Hyperparathyroidism Hyperparathyroidism 
Vasculitis Vasculitis 
Vitiligo Vitiligo 
Polymyalgia Rheumatica Pernicious Anaemia 
Idiopathic Thrombocytopenia Purprua Temporal Arteritis 
Type 1 Diabetes Mellitus >2 autoimmune diseases 
Systemic Lupus Erythematosus  
Erythema Nodosum  
Sjogren’s Syndrome  
Myasthenia Gravis  
Multiple Sclerosis  
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Supplementary Data 
 
Appendix 1 
 
Search strategy and selection criteria 
Publications were identified by computerised search of the MEDLINE (OVID) 
database, from 1966 to date.  Other sources included reference books and 
selected references from affiliated bibliographies.  Studies were considered 
for inclusion if they were written in the English language and had relevant 
applications to the elderly population. 
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